What Happened

GSK reported positive results from its dual global Phase III trials, B-Well 1 and B-Well 2, evaluating bepirovirsen for chronic hepatitis B. The trials met their primary endpoints, with significantly higher rates of functional cure—defined as sustained HBsAg loss and undetectable viral DNA for at least 24 weeks after treatment—compared with standard care alone.

Bepirovirsen is an antisense oligonucleotide licensed from Ionis Pharmaceuticals that targets hepatitis B virus RNA to reduce viral protein expression. GSK plans to begin global regulatory submissions for the drug in the first quarter of 2026.

Who Is Affected

GSK is the primary protagonist, advancing bepirovirsen as a potential time-limited backbone therapy for chronic hepatitis B. The trials enrolled more than 1,800 adults across 29 countries who were on stable nucleos(t)ide analogue therapy.

The broader competitive landscape includes Brii Biosciences, which presented Phase II ENSURE data at AASLD 2025, as well as AusperBio, which is developing AHB-137, and Precision BioSciences, which is evaluating the gene editing candidate PBGENE-HBV.

Market Impact

Positive Phase III data and upcoming regulatory submissions create a new commercial launch cycle for GSK, with implications for market access, RWE, and patient support teams. Competitor programs are also advancing, indicating a crowded and active hepatitis B functional cure market.

• GSK's regulatory submissions in Q1 2026 will drive near-term needs for regulatory affairs, launch analytics, and commercial planning support.
• Rivals such as Brii Biosciences, AusperBio, and Precision BioSciences are progressing their own functional cure candidates, intensifying competitive intelligence and market positioning requirements.
• Because functional cure may enable finite treatment, future launch strategy will need to address pricing, reimbursement, and long-term outcomes data.

What to Watch

Watch for GSK's actual regulatory filings in early 2026 and subsequent FDA and EMA review timelines. Also monitor the full Phase III safety data set, which GSK said was consistent with earlier studies, as it will be scrutinized during regulatory review.

Keep an eye on competitor data readouts—especially Brii Biosciences' Phase II ENSURE study results and AusperBio's global Phase II/III program—as they will shape the commercial positioning and differentiation of any approved functional cure.

Related coverage

• FDA approves Zanvastro, first drug to treat Alexander disease, developed by Ionis Pharmaceuticals
• Ionis’ Zanvastro approved as first-ever Alexander disease treatment
• GSK plans 1,200+ layoffs at Belgium sites as $2.5B restructure gains momentum
• GSK to lay off over 1,200 roles in Belgium as cost-saving program picks up steam